Myfembree approval gives Myovant, Pfizer avenue to market share in endometriosis

A label expansion in endometriosis will give Myovant and Pfizer a chance to win market share in an endometriosis market in which it will now compete with AbbVie’s Orilissa.

On Friday, FDA approved Myfembree relugolix/estradiol/norethindrone, a combination centering on GNRHR antagonist relugolix, to manage moderate to severe pain associated with endometriosis. Myovant Sciences Ltd. (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) already market the drug to treat heavy menstrual bleeding associated with uterine fibroids; relugolix is also approved as Orgovyx to treat prostate cancer...